Company Encyclopedia
View More
name
Immunovant
IMVT.US
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc.
1.945 T
IMVT.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Douglas Hughes Sells 15,000 Shares of Immunovant (NASDAQ:IMVT) Stock

    Immunovant directors Douglas Hughes and Andrew Fromkin sold shares, reducing their positions by 11.05% and 20.58%, respectively. Hughes sold 15,000 shares for $348,600, while Fromkin sold 22,249 shares for $517,289. The stock rose 3.1% to $22.71, with a market cap of $3.98 billion. Analysts rate the stock as "Moderate Buy" with a target of $28.78.

    Market Beat·
    US
    IMVT
    -1.00%
    Market Beat·
    US
    IMVT
    -1.00%

    Officer Geffner Files To Sell 50,000 Of Immunovant Inc [IMVT]

    Officer Michael Geffner of Immunovant Inc filed a Form 144 with the SEC to sell 50,000 shares on November 26, 2025. The sale will be brokered by Morgan Stanley Smith Barney LLC. Form 144 is required for selling restricted securities, allowing sales within 90 days of filing.

    Reuters·
    US
    IMVT
    -1.00%
    Reuters·
    US
    IMVT
    -1.00%

    Officer Geffner Files To Sell 103,897 Of Immunovant Inc [IMVT]

    Officer Michael Geffner of Immunovant Inc filed a Form 144 with the SEC to sell 103,897 restricted shares on November 25, 2025. The sale will be brokered by Morgan Stanley Smith Barney LLC. Form 144 is required for selling restricted stock, allowing sales within 90 days of filing. The Washington Service offers insider trading analysis and data services.

    Reuters·
    US
    IMVT
    -1.00%
    Reuters·
    US
    IMVT
    -1.00%

    Immunovant Insider Sold Shares Worth $298,237, According to a Recent SEC Filing

    04:28 PM EST, 11/21/2025 (MT Newswires) -- Melanie Gloria, Chief Operating Officer, on November 20, 2025, sold 12,626 shares in Immunovant ( IMVT ) for $298,237. Following the Form 4 filing with the SEC, Gloria has control over a total of 173,511 common shares of the company, with 173,511 shares held directly.SEC Filing: MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

    fidelity·
    US
    IMVT
    -1.00%
    fidelity·
    US
    IMVT
    -1.00%

    Immunovant Chief Medical Officer Michael Geffner Departs Amid R&D Restructuring

    Immunovant Inc. announced the departure of Chief Medical Officer Michael Geffner, effective November 21, 2025, as part of an R&D leadership restructuring under CEO Eric Venker. Dr. Geffner will continue consulting for the company until April 30, 2026.

    Reuters·
    US
    IMVT
    -1.00%
    Reuters·
    US
    IMVT
    -1.00%
    © 2025 Longbridge｜Disclaimer